Roland B. Walter
M.S., University of Washington, Epidemiology (Clinical Research), 2011.
Ph.D., University of Washington, Experimental Pathology, 2006.
M.D., University of Zurich, Medicine, 1997.
Dr. Walter's translational research program is focused on human acute myeloid leukemia (AML). He is particularly interested in the preclinical and early clinical development of novel antigen-directed immunotherapies for AML and the delineation of the mechanisms of action and resistance that are clinically relevant for these agents. He is also investigating the molecular and phenotypic characteristics of AML stem and progenitor cells to understand how antigen-directed immunotherapies can be best utilized to eliminate these cells. In clinical studies, Dr. Walter is involved in the conduct of trials testing novel treatments and innovative care approaches for AML patients. Furthermore, in collaborative research, he is taking advantage of large patient datasets to develop and improve diagnostic and prognostic tools in AML.
Honors and Awards
2014-2019, Scholar in Clinical Research Award, Leukemia & Lymphoma Society
2013-2016, ‘A’ Award, Alex’s Lemonade Stand Foundation
2013, Ellermann Price, Swiss Society of Hematology, Switzerland
2012, Corresponding Member, Supreme Council, Swiss Academy of Medical Sciences (SAMS)
2009-2012, Mentored Patient-Oriented Research Career Development Award (K23), National Cancer Institute, National Institutes of Health (NIH), National Institute of Health (NIH)
2006-2009, Special Fellow Career Development Award, Leukemia & Lymphoma Society
2005, SIAK/ESSEX Award in Applied Cancer Research Switzerland
2005, Dr. Ernst Th. Jucker Price for Cancer Research Switzerland
2005-2007, Clinical/Translational Research Scholar Award, American Society of Hematology
2005-2005, Career Development Award, Janggen-Pohn Foundation, Switzerland
2004-2004, Interdisciplinary Dual Mentor Fellowship, Fred Hutchinson Cancer Research Center
2002-2004, Fellowship for Advanced Researchers, Swiss Foundation for Medical-Biological Grants
2008-2010, Research Associate, Fred Hutchinson Cancer Research Center, Clinical Research Division
2008-2010, Acting Instructor in Medicine, University of Washington, Department of Medicine, Division of Hematology
2005-2007, Fellow, University of Washington, Department of Medicine, Division of Hematology
2002-2008, Post-Doctoral Research Fellow, Fred Hutchinson Cancer Research Center, Clinical Research Division
1999-2002, Resident, University of Zurich, Department of Medicine
1997-1999, Resident, Kantonsspital Chur, Department of Medicine
1996-1997, Research Fellow, University of Zurich, Department of Medicine
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2016.
Reply to C.S. Hourigan et al.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016.
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.. Leukemia & lymphoma. :1-4.. 2016.
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.. British journal of haematology. 172(1):134-136.. 2016.
T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.. Current hematologic malignancy reports.. 2016.
Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.. Leukemia research. 45:53-58.. 2016.
How Do Pre-Transplant Peripheral Blood Counts Inform Us About Post-Transplant Outcomes in Acute Myeloid Leukemia? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2015.
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015.
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):559-64.. 2015.
Minimal residual disease in acute myeloid leukemia-current status and future perspectives.. Current hematologic malignancy reports. 10(2):132-44.. 2015.
Antigen-specific immunotherapies for acute myeloid leukemia.. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015(1):584-95.. 2015.
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015.
Minimal residual disease-directed therapy in acute myeloid leukemia.. Blood. 125(15):2331-2335.. 2015.
Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia.. Current hematologic malignancy reports.. 2015.
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(11):1258-64.. 2015.
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.. American journal of hematology. 90(4):295-300.. 2015.